Mesangial injury and cell proliferation are frequent findings in various glomerular diseases in man. Previous studies have demonstrated that basic fibroblast growth factor (bFGF) is a potent mesangial cell mitogen in vitro. To further elucidate the role of bFGF in rat mesangial cell (RMC) proliferation, we examined whether RMC synthesize bFGF in vitro and whether bFGF is involved in mesangial proliferation in vivo. Cultured RMC expressed bFGF protein (23, 21.5, and 18 kD forms) and bFGF mRNA, and released biologically active bFGF into the culture medium after antibody-and complement-mediated injury. Normal rat glomeruli in vivo contained no detectable bFGF mRNA, but bFGF protein (23 and 21.5 kD) could be demonstrated, which immunolocalized to the mesangium. Glomerular bFGF decreased markedly during the acute phase ofglomerulonephritis induced by anti-Thy 1
Introduction
Basic fibroblast growth factor (bFGF)' is expressed by a variety of cells, including fibroblasts, endothelial cells, vascular smooth muscle cells, and macrophages (reviewed in reference 1). Because of the lack of a signal sequence characteristic of secreted proteins, the mode ofcellular bFGF release is unclear.
However, lethal cell injury has been shown to liberate intracellular bFGF (reviewed in reference 2). In instances of sublethal cell injury, active bFGF has been shown to be released from its cytosolic storage sites through plasma membrane disruptions (3) . Basic FGF is also bound with low affinity to heparan sulfate proteoglycans in extracellular matrices, where it is released by heparin and heparitinases (4, 5) . A central biological effect of bFGF is the induction of proliferation in various cultured cells, including fibroblasts, endothelial cells, and vascular smooth muscle cells (1) . Recent data also emphasize the role of bFGF in the regulation ofcell proliferation in vivo, as infusion of bFGF into rats stimulated endothelial and smooth muscle cell proliferation in injured arteries (6) and injection of a neutralizing antibody to bFGF inhibited smooth muscle cell proliferation after vascular injury (7) .
Although bFGF has been isolated from whole kidney homogenates (8) , to date no studies have addressed either the renal localization of bFGF or a functional role for bFGF in glomerular diseases. However, in vitro experiments performed with the smooth musclelike glomerular mesangial cells have demonstrated the mitogenicity of bFGF for these cells (9) . In the present study, we have extended these in vitro observations to the in vivo situation by investigating the anti-Thy 1. 1 mesangial proliferative glomerulonephritis model in rats. Anti-Thy 1.1 glomerulonephritis is a well-characterized model ( 10-14), induced by injection of an anti-mesangial cell antibody (antiThy 1.1 ) which leads to an acute phase of complement-dependent mesangial cell lysis followed by a phase of intense mesangial cell proliferation (10) (11) (12) . The relevance of this model for human glomerular diseases is emphasized by the observation that very similar features, namely mesangial cell degeneration or necrosis with disruption ofthe normal glomerular mesangial architecture and matrix dissolution (mesangiolysis), as well as proliferation ofmesangial cells, can be documented in a variety ofrenal diseases in man, including diabetic nephropathy, acute glomerulonephritis, IgA nephropathy, diffuse lupus nephritis, and renal transplant rejection ( 15, 16) . Furthermore, the occurrence of anti-mesangial cell autoantibodies has recently been documented in IgA-nephropathy and Henoch-Schonlein purpura ( 17) .
In the present study, we demonstrate that cultured rat glomerular mesangial cells produce bFGF and release it in re-sponse to antibody-mediated mesangial cell injury. We also demonstrate that in the anti-Thy 1.1 glomerulonephritis model glomerular bFGF decreases during the early mesangiolysis, suggesting release, and that bFGF mRNA and protein within glomerular cells increase above normal during the subsequent mesangial proliferative phase. Furthermore, we show that bFGF is mitogenic for mesangial cells both in vitro and in vivo. Thus, bFGF released from damaged mesangial cells may have an important role in the mesangial cell proliferation that occurs in various glomerular diseases.
Methods
Reagents. Recombinant human bFGF (rh-bFGF) was kindly provided by Synergen, Boulder, CO. Two murine monoclonal IgG, antibodies against rh-bFGF (DE6 and DG2) were kind gifts of T. Reilly, DuPont-Merck (Wilmington, DE) (18) . Affinity-purified polyclonal rabbit anti-rh-bFGF antibody was prepared as described previously (7) . Recombinant human acidic FGF was obtained from Upstate Biotechnology Inc. (Lake Placid, NY).
Experiments with cultured rat mesangial cells. Rat mesangial cells were prepared from collagenase-digested glomeruli, as previously described ( 19) . Cells were seeded into six well tissue culture dishes (Corning Glass Works, Corning, NY). After confluency they, were growth arrested for 24 h in medium ( 19) containing 0.5% FCS (Gibco Laboratories, Grand Island, NY). 5% normal human serum (nonheated or heat-inactivated for 30 min at 56°C) and 5 mg/ml anti-Thy 1.1 IgG ( 14) or normal goat IgG were then added for 4 h, after which the bFGF content in the supernatant was determined by ELISA (see below). The mitogenicity of rh-bFGF for growth-arrested rat mesangial cells was examined in 24-well tissue culture dishes (Corning Glass Works) in which the cells were incubated for 24 h with or without bFGF. After 20 h, 2.5 MCi [3H]thymidine (Du Pont-Merck) were added to each well, and the radioactivity incorporated into the cell layer was measured at 24 h as previously described (20) .
The bioactivity of bFGF released from mesangial cells was determined by examining the [3H]thymidine incorporation rates into growth arrested, subconfluent (see above) murine Swiss 3T3 fibroblasts stimulated with mesangial cell supernatants. The supernatants were preincubated with either 0.5 Mg DG2 antibody or irrelevant mouse IgG, per nanogram of bFGF, as previously described (7) . Cellular protein and total RNA were extracted from proliferating, 80-90% confluent mesangial cells and used for immunoblotting and Northern analysis as described below. bFGF ELISA. A bFGF ELISA was established using principles described previously (21 ) . Briefly, wells of microtitration plates (Nunc, Roskilde, Denmark) were coated with 0.25 Mg DE6 anti-bFGF antibody. The wells were blocked with 0.2% casein (Sigma Chemical Co., St. Louis, MO), and subsequently incubated with the samples followed by 0.8 Mg/well secondary antibody (an IgG fraction of polyclonal rabbit anti-bFGF [7] ). Bound secondary antibody was detected with a biotinylated goat anti-rabbit IgG antibody ( 1:400, Vector Laboratories, Burlingame, CA), streptavidin-peroxidase (Vector Laboratories,) and subsequent color development. The detection limit of the ELISA was 0.4 ng/ml bFGF and no crossreactivity with acidic FGF (up to 1,000 ng/ml) was observed.
In vivo model. Anti-Thy 1.1 mesangial proliferative glomerulonephritis was induced in 30 Wistar rats by injection of anti-rat thymocyte plasma (0.5 ml/ 100 g body wt i.v.) (11, 14) . Six additional rats were also complement depleted with cobra venom factor (CVF) ( 14). In these latter rats, serum C3 levels, measured by radial immunodiffusion ( 14), of < 10% baseline value were maintained throughout the study period. Six normal Wistar rats were studied as controls. heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) in 0.9% saline followed by saline only for 15 min into the right renal artery using previously described techniques (22) . Renal biopsies were obtained from the left kidney before the infusion and from the right kidney at 15 min after the infusion. Biopsies were immunostained for bFGF.
The mitogenicity ofrecombinant human bFGF for glomerular cells in vivo was examined in normal Wistar rats, as well as in Wistar rats that had received a subnephritogenic dose of anti-rat thymocyte plasma (0.1 ml/ 100 g body wt) at 24 hours before the experiment. The rats received a bolus injection of either 40 Ag bFGF or vehicle (0.3 M glycerin in 10 mM PBS, pH 7.4) into a tail vein and renal biopsies were obtained on days 1, 2, and 4 after the injection and immunostained for proliferating cells (see below).
Renal morphology and immunohistochemistry. Renal biopsies were fixed in methyl Carnoy's solution ( I1) and embedded in paraffin. Mesangiolysis was graded semiquantitatively in periodic acid-Schiffstained sections on a scale from 0-4+ as previously described ( 12) . Immunoperoxidase staining was performed as described previously ( 11) using the following primary antibodies: DE6 or DG2 (bFGF); 19A2 (American Biotech Inc., Plantation, FL), a murine IgM monoclonal antibody against the proliferating cell nuclear antigen (PCNA) (11); and EDl (Bioproducts for Science, Inc., Indianapolis, IN), a murine monoclonal IgG, antibody to monocytes and macrophages.
Additionally, glomerular bFGF expression was examined on 4-Mm sections of frozen, ethanol/ether-fixed kidney tissue ( 13 ) using a polyclonal anti-bFGF antibody (7) . Negative controls consisted of substitution ofthe primary antibody with equivalent concentrations ofan irrelevant murine monoclonal antibody or normal rabbit IgG. For each biopsy, > 20 cross sections ofglomeruli containing > 20 discrete capillary segments each were evaluated by an observer, who was unaware of the origin of the slides. Glomerular bFGF expression was graded semiquantitatively, based on the extent of mesangial staining, as 0-5% (grade 0); 5-25% (I), 25-50% (II), 50-75% (III), or > 75% (IV) ofthe glomerular tuft showing positive staining ( 13) .
Double immunostaining was performed as reported previously (12) by first staining the sections for PCNA, followed by staining for either bFGF (DE6) or mesangial cells (OX-7, a murine monoclonal anti-Thy 1.1; Accurate Chem. & Sci. Corp., Westbury, NY). Negative controls consisted of omission of either of the primary antibodies.
Immunoblotting of bFGF. Cultured mesangial cells and isolated glomeruli ( 1) were lysed as described (7) . The samples were reduced with 50 mM DTT (Sigma Chemical Co.) and electrophoresed through a 5% stacking, 12.5% separating SDS-PAGE gel (21) . The lanes were loaded with either 150 ,g of protein extracted from cultured cells, or the protein extracted from 1,500 glomeruli (as determined by counting the isolated glomeruli before lysis). The electrophoresed proteins were transferred to nitrocellulose filters by electroblotting and were immunostained (21 ) with the DE6 or DG2 antibody oran irrevelevant monoclonal antibody as primary antibodies.
Preparation of RNA and Northern analysis. Total RNA was extracted from cultured cells or from three separate glomerular preparations ( 11 ) using RNAzol BR (Cinna/Biotecx Laboratories, Friendswood, TX) followed by a LiCl precipitation as described previously (23) . Northern analysis was performed as described ( 12) Immunofluorescent staining of methanol-fixed, subconfluent mesangial cells revealed bFGF in a granular pattern in the cytoplasm (Fig. 1) . Immunoblotting using either the DE6 (Fig. 2) or DG2 antibody demonstrated the presence of 23-, 21.5-, and 1 8.0-kD bFGF forms in mesangial cell lysates. Furthermore, 6.8-kb bFGF mRNA transcripts were present in total mesangial cell RNA (Fig. 3) .
Anti-mesangial cell antibody and complement induce release of biologically active bFGF from mesangial cells. The mesangial cell release of bFGF was investigated in growtharrested cells that had been injured with 5 mg/ml anti-Thy 1. IgG and 5% normal human serum as a complement source. In preliminary experiments, we had observed that these concentrations of antibody and complement resulted in lethal cell injury, as judged by cellular release of5Cr (data not shown). In the supernatant of lethally injured mesangial cells, bFGF concentrations increased from nondetectable levels at the start of the experiment to 1.58±0.67 ng/ml (n = 5) after 4 h. This increase in the extracellular bFGF concentration appeared to reflect cellular release of preformed bFGF rather than increased synthesis, since immunofluorescent staining of the cells after 4 h of stimulation with anti-Thy 1. antibody and complement showed an almost complete loss ofcellular bFGF staining (data not shown). Basic FGF levels in the cell supernatant remained below the ELISA detection threshold (< 0.4 ng/ ml) after 4 h of incubation with either normal goat IgG plus complement, anti-Thy 1. antibody plus heat-inactivated complement or with a nonlytic concentration of anti-Thy 1. plus complement (n = 3 each). Furthermore, no bFGF was detectable in supernatants of actively proliferating, nonmanipulated cells at 24 or 72 h after changing the medium (n = 5).
To determine the bioactivity of mesangial cell bFGF, murine Swiss 3T3 fibroblasts, which are growth responsive to bFGF (Table I) , were incubated with mesangial cell superna- tibody and heat-inactivated complement, no reduction of the fibroblast proliferation rate was observed after preincubation of the supernatant with the anti-bFGF antibody (Table I) . bFGF is expressed in glomeruli of normal rats. Positive bFGF immunostaining using the DE6 (Fig. 4 A) or DG2 antibFGF antibodies was observed in the mesangium ofnormal rat glomeruli. Staining of other glomerular cells was weak or absent. No staining ofthe glomerular basement membrane, using either an immunoperoxidase (Fig. 4 A) or immunofluorescence procedure, was apparent. Positive glomerular bFGF staining was also observed when frozen kidney sections were stained with the polyclonal anti-bFGF antibody (data not shown). However, in this case, the less well-preserved morphology prevented the localization of the staining to specific glomerular substructures. Intrarenal infusion of heparin into normal rats did not affect the glomerular bFGF staining pattern to a detectable degree (n = 4; data not shown), suggesting that the majority of the glomerular bFGF was located intracellularly (26) . Apart from the glomerular tuft, bFGF immunostaining using the DE6 antibody in the renal cortex was positive in the glomerular capsule, the wall of blood vessels, the interstitium, distal tubules, and collecting ducts.
Immunoblotting using either the DE6 (Fig. 2) (Fig. 3) .
Basic characteristics ofthe mesangioproliferative glomerulonephritis model. The injection of anti-Thy 1.1 antibody into rats resulted in acute mesangiolysis on days 1 and 2 (Table II) . Significant glomerular cell proliferation was observed between days 2 and 6 (Table II) . Double immunostaining of biopsies obtained on days 2, 4, and 6 (Table III) showed that at any time point, the majority of proliferating glomerular cells also stained with a mesangial cell marker (anti-Thy 1.1 ), which was in contrast to normal glomeruli, where the majority of proliferating cells were nonmesangial (presumably endothelial cells (27) ). On day 14, glomerular cell proliferation had returned to the normal range (Table II) , although many glomeruli still exhibited hypercellularity and mesangial matrix expansion. Marked glomerular monocyte/macrophage infiltration was noted on day 1, after which it decreased, but still remained elevated in comparison with normal rats on days 2, 4, and 6 (Table II) . Complement depletion before disease induction abolished all aforementioned pathological changes on day 4 (Table II) . Glomerular bFGF expression during mesangioproliferative glomerulonephritis. Fig. 4 B and Table II show that the glomerular area immunostaining for bFGF using either the monoclonal DE6 antibody or a polyclonal anti-bFGF antibody decreased concurrently with the mesangiolysis on days 1 and 2 after disease induction. At all later stages, the glomerular area staining for bFGF was significantly increased in comparison with normal glomeruli (Fig. 4 C and Table II ). Areas of increased bFGF staining frequently corresponded to areas of hypercellularity (Fig. 4 C) . Double immunostaining for proliferating cells (PCNA-positive) and bFGF showed that the majority of proliferating cells also stained positive for bFGF on day 4 (78±6% of glomerular PCNA-positive cells) and day 6 (76±5%). In contrast, immunostaining of 2-um serial sections for bFGF and monocytes/macrophages (ED 1) failed to reveal not shown). As in normal rats, intrarenal infusion of heparin into rats Immunoblotting using either the DE6 (Fig. 2) or DG2 antiwith anti-Thy 1.1 nephritis on day 5 did not affect the glomerubFGF antibody confirmed the decrease of the glomerular bFGF content on day 1 with a subsequent increase of21.5-and 23-kD bFGF at days 4 and 6. Immunoblotting also suggested the appearance ofa very weak 1 8-kD bFGF band at these latter time points (Fig. 2) . Whereas bFGF mRNA transcripts could not be demonstrated in glomerular RNA extracted from normal rats or from rats on day 1 after disease induction by Northern analysis, a 6.8-kb transcript was identified in glomerular RNA from rats on 4, 6, and 14 d after anti-Thy 1. 1 antibody injection (Fig. 3) .
Complement depletion before disease induction prevented the increase in bFGF mRNA and protein expression on day 4 (Figs. 2 and 3, and Table II (Table IV) . In contrast, if rats received a subnephritogenic dose ofanti-Thy 1.1 antibody followed 24 h later by 40 ,ug bFGF, the number of proliferating glomerular cells increased (Table IV) . On day 4 after the bFGF injection, glomerular cell proliferation had returned to the normal range again (Table IV) . Double immunostaining ofrenal biopsies from rats that had received anti-Thy 1.1 antibody plus bFGF showed that most of the proliferating glomerular cells stained with a mesangial cell marker (anti-Thy 1.1; 63±10% on day 1 and 57±9% on day 2), but not with a monocyte/macrophage marker (EDl; < 3% on days 1 and 2). 22±11% (24 h) and 23±4% (48 h) of the proliferating glomerular cells were identified as nonmesangial cells, while the remainder could not be classified with certainty as either mesangial or nonmesangial.
Discussion
In agreement with previous findings of Silver et al (9) (31 ) . The nondetectable levels of bFGF in the culture medium of nonstimulated, growth arrested or actively proliferating mesangial cells is likely to reflect the lack of a signal peptide, indicative of secreted proteins, in the bFGF molecule (32) . In preliminary experiments, we have also been unable to detect cellular release of bFGF after stimulating serum-starved mesangial cells for 24 h with various agonists, including platelet-derived growth factor, tumor necrosis factor-a, IL-1I , IL-6, transforming growth factor-f, lipopolysaccharide, or FCS (J. Floege, unpublished observations). In contrast to these various conditions, mesangial cell release of biologically active bFGF into the culture medium was noted upon lethal mesangial cell injury with antiThy 1.1 antibody and complement. The data presented in Table I suggest that bFGF was one of the fibroblast mitogens released from the injured mesangial cells.
Isoforms of bFGF similar to those detected in cultured rat mesangial cells were found in glomerular lysates ofnormal rats. In agreement with findings in a variety of other tissues (24) , bFGF mRNA levels in normal glomerular RNA were below the limits of detection, supporting the notion (24) bFGF receptors. However, binding of bFGF to the glomerular extracellular matrix during the early stages of anti-Thy 1.1 nephritis appears unlikely, since the mesangial matrix at this time is severely disrupted and heparan sulfate proteoglycan staining decreased ( 13) . Binding of released bFGF to cells has been shown to result in fast bFGF removal, since bound bFGF is rapidly internalized, followed by intracellular degradation (34) . This latter observation in particular may explain how released bFGF can exert significant biological effects, such as induction of growth, despite an almost complete loss of bFGF from the injured tissue as observed in early anti-Thy 1.1 nephritis.
After the initial mesangiolysis, marked proliferation ofmesangial cells ensues in the anti-Thy 1.1 glomerulonephritis (this study and reference 12) . Our data show that this proliferative response was associated with increased glomerular synthesis of bFGF. These findings strongly suggest that the glomerular bFGF in normal and diseased rats is largely derived from mesangial cells. However, we cannot exclude the presence of low amounts of bFGF, especially in glomerular endothelial cells, since endothelial cells of different origin have been shown to synthesize bFGF (35, 36) . Despite a report on the presence of bFGF in peritoneal macrophages (37) , glomerular monocytes/macrophages do not appear to contribute significantly to the glomerular bFGF, since during the marked macrophage infiltration on day 1 after disease induction, glomerular bFGF became nearly undetectable and no bFGF immunostaining of monocytes/macrophages was observed.
In addition to the presence of bFGF in glomerular mesangial cells, observations in other tissues have shown that subsequent to its cellular release, bFGF binds to and is probably stored by heparan sulfate molecules in the extracellular matrix. Biologically active bFGF can then be released from the matrix by either heparin or heparan sulfate-degrading enzymes (4, 5 (38) . Interestingly, however, administration ofa neutralizing anti-PDGF antibody in vivo did not block the initial (day 2) glomerular cell proliferation, but only affected the proliferation rate on day 4 (39) . The present study suggests that the initial nonresponsiveness to anti-PDGF antibody may result from the mediation of the early proliferative phase by other growth factors such as bFGF released from damaged mesangial cells. This assumption is supported by our finding that similar to observations in normal and injured vessels of bFGF-infused rats (6), injured mesangial cells (but not normal mesangial cells) were susceptible to bFGF-induced proliferation in vivo. The reason(s) for the increased responsiveness of injured mesangial cells to the mitogenic effects of bFGF remains unknown, although it has been suggested that upregulation of bFGF receptors after cellular injury may be involved (6) . Alternatively, the accessibility of bFGF to mesangial cells in vivo may depend on the previous (subclinical) disruption of the normal extracellular matrix. However, this latter possibility is not supported by in vivo findings in vascular endothelial cells, which despite continuous exposure to injected, circulating bFGF were growth responsive towards bFGF only after injury (6) . The observation that only injured mesangial cells in vivo appear to be growth responsive to bFGF is also consistent with the finding of a mitogenic effect of bFGF on cultured mesangial cells. Thus, mesangial cells in vitro have been shown to express a-smooth muscle actin (40) , to secrete predominantly interstitial types of collagen (41 ) , and to proliferate even under serum-free conditions (42) , and thereby exhibit various features characteristic of injured rather than normal mesangial cells in vivo (1 1-13 ).
In contrast to the potential involvement of bFGF in the initiation of mesangial cell proliferation during the early phase of anti-Thy 1.1 nephritis (days 1 and 2), our data do not support a role for bFGF in the later phases of mesangial cell proliferation (anti-Thy 1.1 nephritis days 4 and 6). Thus, as mentioned above, neither the induction of mesangial cell proliferation in vitro with cytokines such as PDGF nor the stimulation of the cells with various other cytokines resulted in a detectable bFGF release. These findings are consistent with the apparent absence of bFGF in the glomerular extracellular matrix during the peak of mesangial cell proliferation in the anti-Thy 1.1 model, and suggest that the marked increase in glomerular bFGF gene and protein expression during anti-Thy 1.1 nephritis reflects mainly a reconstitution of the physiologic mesangial cell content of bFGF. On the other hand, we can not exclude that transient cellular overproduction of bFGF may result in an autocrine mitogenic signal through hypothetical intracellular signaling pathways involving nuclear bFGF-receptors (43) .
In conclusion, the present study provides the first evidence that glomerular mesangial cells in vivo are capable of synthesizing bFGF, that they may release bioactive bFGF in response to injury, and that bFGF is mitogenic for injured mesangial cells. Mesangiolysis, as an indication of mesangial injury, has been noted in a variety of human glomerular diseases ( 15 ) . In the presence of constitutive mesangial bFGF expression, this study suggests that mesangial injury and subsequent release ofbFGF may be an important mechanism involved in the onset of mesangial hyperplasia in man. Experimental ( 13, 23, 44) as well as clinical (45) observations support the notion (46) that this onset of mesangial cell proliferation may be a critical predecessor for the development of mesangial matrix expansion and ultimately, glomerulosclerosis.
